Cipla : Disclosure of Related Party Transactions for the half year ended 31st March 2024

May 11, 2024 at 12:14 am

10th May 2024
(1) BSE Ltd	(2) National Stock Exchange of India Ltd
Listing Department	Listing Department
Phiroze Jeejeebhoy Towers	Exchange Plaza, 5th floor
Dalal Street	Plot no. C/1, G Block
Mumbai - 400 001	Bandra Kurla Complex
Scrip Code: 500087	Bandra (East), Mumbai - 400 051
	Scrip Code: CIPLA

SOCIETE DE LA BOURSE DE LUXEMBOURG Societe Anonyme
35A Boulevard Joseph II L-1840 Luxembourg

Sub: Disclosure of related party transactions for the half-yearended 31st March 2024

Dear Sir/Madam,

Pursuant to Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the disclosure of related party transactions, for the half-year ended 31st March 2024.

The disclosure is also being uploaded on the website of the Company: www.cipla.com.

Kindly take the above information on record.

Thanking you,

Yours faithfully,

For Cipla Limited

RAJENDR

KUMAR CHOPRA

Digitally signed by RAJENDRA KUMAR CHOPRA Date: 2024.05.10 23:52:22 +05'30'

Rajendra Chopra

Company Secretary

Encl.: as above

Prepared by: Y. Navya Sri Swathi

Cipla Ltd.

Regd. Office - Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai-400 013, India

P +91 22 41916000 F +91 22 41916120 Wwww.cipla.com E-mailcontactus@cipla.comCorporate Identity Number L24239MH1935PLC002380

Disclosure of related party transactions for the half year ended 31st March, 2024

	Details of the party (listed entity /subsidiary)		Details of the counterparty
	entering into the transaction
Sr No.

						Type of related party transaction	Details of other related party
					Relationship of the counterparty	transaction

	Name	PAN	Name	PAN	with the listed entity or its
					subsidiary
1	Cipla Limited		Aspergen Inc.		Holding- Subsidiary	Any other transaction	Reimbursement Charges
							Received
2	Cipla Limited		Aspergen Inc.		Holding- Subsidiary	Sale of goods or services
3	Cipla Limited		Breathe Free Lanka (Private) Limited		Holding- Subsidiary	Any other transaction	Reimbursement Charges Paid
4	Cipla Limited		Breathe Free Lanka (Private) Limited		Holding- Subsidiary	Any other transaction	Reimbursement Charges
							Received

			In case monies are
			due to either party as
			a result of the
Value of the related party	Remarks on approval	Value of transaction
transaction as approved	by audit committee	during the reporting
by the audit committee	period	Opening	Closing

			balance	balance
1.00	Approved	0.09	-	-
15.00	Approved	1.45	-	-
1.38	Approved	1.38	-	-
1.00	Approved	0.18	-	-

Rs. Cr

Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed

entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.

In case any financial indebtedness is incurred to
make or give loans, inter-corporate deposits,		Details of the loans, inter-corporate deposits, advances or investments
advances or investments
Nature of			Nature (loan/				Purpose for which the funds Notes
indebtedness	Details of		advance/
				will be utilised by the
(loan/ issuance of	other	Cost Tenure	intercorporate	Interest Rate (%)	Tenure	Secured/ unsecured
ultimate recipient of funds
debt/ any other	indebtedness		deposit/
				(end usage)
etc.)			investment )

5	Cipla Limited	Breathe Free Lanka (Private) Limited	Holding- Subsidiary	Sale of goods or services		320.00	Approved	90.49	-	-
6	Cipla Limited	Cipla (EU) Limited	Holding- Subsidiary	Any other transaction	Reimbursement Charges Paid	45.00	Approved	0.42	-	-
7	Cipla Limited	Cipla (EU) Limited	Holding- Subsidiary	Any other transaction	Reimbursement Charges	5.00	Approved	0.23	-	-
					Received
8	Cipla Limited	Cipla (EU) Limited	Holding- Subsidiary	Sale of goods or services		200.00	Approved	30.84	-	-
9	Cipla Limited	Cipla (EU) Limited	Holding- Subsidiary	Purchase of goods or services		26.68	Approved	17.33	-	-
10	Cipla Limited	Cipla (EU) Limited	Holding- Subsidiary	Sale of goods or services		3.00	Approved	2.02	-	-
11	Cipla Limited	Cipla (EU) Limited	Holding- Subsidiary	Investment		1,760.00	Approved	177.32	-	-
12	Cipla Limited	Cipla (Jiangsu) Pharmaceutical Co., Ltd.	Holding- Subsidiary	Any other transaction	Reimbursement Charges	12.00	Approved	0.13	-	-
					Received
13	Cipla Limited	Cipla Colombia SAS	Holding- Subsidiary	Any other transaction	Reimbursement Charges	1.00	Approved	0.04	-	-
					Received
14	Cipla Limited	Cipla Colombia SAS	Holding- Subsidiary	Sale of goods or services		70.00	Approved	24.26	-	-
15	Cipla Limited	Cipla Digital Health Limited	Holding- Subsidiary	Any other transaction	Reimbursement Charges	1.00	Approved	0.04	-	-
					Received
16	Cipla Limited	Cipla Digital Health Limited	Holding- Subsidiary	Any other transaction	Royalty Income	1.00	Approved	0.00	-	-
17	Cipla Limited	Cipla Digital Health Limited	Holding- Subsidiary	Sale of goods or services		3.00	Approved	0.91	-	-
18	Cipla Limited	Cipla Digital Health Limited	Holding- Subsidiary	Investment		20.00	Approved	10.00	-	-
19	Cipla Limited	Cipla Europe NV	Holding- Subsidiary	Any other transaction	Reimbursement Charges Paid	1.00	Approved	0.05	-	-
20	Cipla Limited	Cipla Europe NV	Holding- Subsidiary	Any other transaction	Reimbursement Charges	1.50	Approved	0.05	-	-
					Received
21	Cipla Limited	Cipla Europe NV	Holding- Subsidiary	Sale of goods or services		300.00	Approved	17.57	-	-
22	Cipla Limited	Cipla Europe NV	Holding- Subsidiary	Sale of goods or services		1.00	Approved	0.34	-	-
23	Cipla Limited	Cipla Foundation	The entity over which KMP or	Any other transaction	Donation paid	69.34	Approved	27.29	-	-
			relative of KMP are able to
			exercise significant influence
24	Cipla Limited	Cipla Gulf FZ-LLC	Holding- Subsidiary	Any other transaction	Reimbursement Charges Paid	7.00	Approved	0.02	-	-
25	Cipla Limited	Cipla Gulf FZ-LLC	Holding- Subsidiary	Any other transaction	Reimbursement Charges	1.00	Approved	0.02	-	-
					Received
26	Cipla Limited	Cipla Gulf FZ-LLC	Holding- Subsidiary	Sale of goods or services		150.00	Approved	68.26	-	-
27	Cipla Limited	Cipla Gulf FZ-LLC	Holding- Subsidiary	Purchase of goods or services		22.00	Approved	2.28	-	-
28	Cipla Limited	Cipla Gulf FZ-LLC	Holding- Subsidiary	Sale of goods or services		1.50	Approved	0.16	-	-
29	Cipla Limited	Cipla Health Limited	Holding- Subsidiary	Interest received		2.26	Approved	2.26	-	-
30	Cipla Limited	Cipla Health Limited	Holding- Subsidiary	Any other transaction	Loan repaid	-		15.00	-	-
31	Cipla Limited	Cipla Health Limited	Holding- Subsidiary	Purchase of goods or services		137.00	Approved	32.50	-	-
32	Cipla Limited	Cipla Health Limited	Holding- Subsidiary	Any other transaction	Reimbursement Charges Paid	40.00	Approved	9.40	-	-
33	Cipla Limited	Cipla Health Limited	Holding- Subsidiary	Any other transaction	Royalty Income	30.25	Approved	8.63	-	-
34	Cipla Limited	Cipla Health Limited	Holding- Subsidiary	Sale of goods or services		6.00	Approved	0.12	-	-
35	Cipla Limited	Cipla Health Limited	Holding- Subsidiary	Purchase of goods or services		2.00	Approved	0.41	-	-
36	Cipla Limited	Cipla Health Limited	Holding- Subsidiary	Sale of goods or services		75.00	Approved	28.47	-	-
37	Cipla Limited	Cipla Holding B.V.	Holding- Subsidiary	Any other transaction	Reimbursement Charges	2.00	Approved	0.18	-	-
					Received
38	Cipla Limited	Cipla Holding B.V.	Holding- Subsidiary	Purchase of goods or services		14.00	Approved	3.16	-	-
39	Cipla Limited	Cipla Holding B.V.	Holding- Subsidiary	Sale of goods or services		2.00	Approved	0.13	-	-
40	Cipla Limited	Cipla Kenya Limited	Holding- Subsidiary	Any other transaction	Commission Paid	20.00	Approved	4.38	-	-
41	Cipla Limited	Cipla Kenya Limited	Holding- Subsidiary	Any other transaction	Reimbursement Charges Paid	1.00	Approved	0.58	-	-
42	Cipla Limited	Cipla Kenya Limited	Holding- Subsidiary	Any other transaction	Reimbursement Charges	1.00	Approved	0.15	-	-
					Received
43	Cipla Limited	Cipla Kenya Limited	Holding- Subsidiary	Sale of goods or services		45.00	Approved	7.85	-	-
44	Cipla Limited	Cipla Kenya Limited	Holding- Subsidiary	Sale of goods or services		1.00	Approved	0.28	-	-
45	Cipla Limited	Cipla Limited Employees Provident fund	Post employment benefit trust	Any other transaction	Contribution to Provident	150.00	Approved	24.78	-	-
					Fund
46	Cipla Limited	Cipla Malaysia Sdn. Bhd.	Holding- Subsidiary	Any other transaction	Reimbursement Charges	1.00	Approved	0.04	-	-
					Received
47	Cipla Limited	Cipla Malaysia Sdn. Bhd.	Holding- Subsidiary	Purchase of goods or services		15.00	Approved	3.86	-	-
48	Cipla Limited	Cipla Medpro Manufacturing (Pty) Limited	Holding- Subsidiary	Any other transaction	Freight Charges Received	1.00	Approved	0.02	-	-
49	Cipla Limited	Cipla Medpro Manufacturing (Pty) Limited	Holding- Subsidiary	Any other transaction	Reimbursement Charges	1.00	Approved	0.02	-	-
					Received
50	Cipla Limited	Cipla Medpro Manufacturing (Pty) Limited	Holding- Subsidiary	Sale of goods or services		50.00	Approved	0.37	-	-
51	Cipla Limited	Cipla Medpro Manufacturing (Pty) Limited	Holding- Subsidiary	Sale of goods or services		1.87	Approved	1.87	-	-
52	Cipla Limited	Cipla Medpro South Africa	Holding- Subsidiary	Any other transaction	Royalty Income	80.00	Approved	23.39	-	-
		(Pty) Limited
53	Cipla Limited	Cipla Medpro South Africa	Holding- Subsidiary	Sale of fixed assets		2.00	Approved	0.88	-	-
		(Pty) Limited
54	Cipla Limited	Cipla Medpro South Africa	Holding- Subsidiary	Interest received		30.33	Approved	30.33	-	-
		(Pty) Limited
55	Cipla Limited	Cipla Pharma and Life Sciences Limited	Holding- Subsidiary	Interest received		1.26	Approved	1.26	-	-
56	Cipla Limited	Cipla Pharma and Life Sciences Limited	Holding- Subsidiary	Loan		350.00	Approved	198.21	-	-
57	Cipla Limited	Cipla Pharma and Life Sciences Limited	Holding- Subsidiary	Purchase of fixed assets		10.00	Approved	0.05	-	-
58	Cipla Limited	Cipla Pharma and Life Sciences Limited	Holding- Subsidiary	Purchase of goods or services		6.00	Approved	0.16	-	-
59	Cipla Limited	Cipla Pharma and Life Sciences Limited	Holding- Subsidiary	Any other transaction	Reimbursement Charges	10.00	Approved	1.10	-	-
					Received

entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.

	Details of the party (listed entity /subsidiary)	Details of the counterparty
	entering into the transaction
Sr No.

	Name	PAN	Name	PAN
60	Cipla Limited		Cipla Pharma and Life Sciences Limited
61	Cipla Limited		Cipla Pharma and Life Sciences Limited
62	Cipla Limited		Cipla Pharma and Life Sciences Limited
63	Cipla Limited		Cipla Pharma and Life Sciences Limited
64	Cipla Limited		Cipla Pharma and Life Sciences Limited
65	Cipla Limited		Cipla Pharma and Life Sciences Limited
66	Cipla Limited		Cipla Pharma and Life Sciences Limited
67	Cipla Limited		Cipla Pharmaceuticals Limited
68	Cipla Limited		Cipla Pharmaceuticals Limited
69	Cipla Limited		Cipla Pharmaceuticals Limited
70	Cipla Limited		Cipla Quality Chemical Industries Limited
71	Cipla Limited		Cipla Select (Pty) Limited
72	Cipla Limited		Cipla USA Inc.
73	Cipla Limited		Cipla USA Inc.
74	Cipla Limited		Cipla USA Inc.
75	Cipla Limited		Cipla USA Inc.
76	Cipla Limited		Cipla USA Inc.
77	Cipla Limited		Cipla USA Inc.
78	Cipla Limited		Cipla USA Inc.
79	Cipla Limited		Cipla USA Inc.
80	Cipla Limited		Clean Max Auriga Power LLP
81	Cipla Limited		Societe Marocaine De Cooperation
			Pharmaceutique (Cooper)
82	Cipla Limited		Exelan Pharmaceuticals Inc.
83	Cipla Limited		Exelan Pharmaceuticals Inc.
84	Cipla Limited		Exelan Pharmaceuticals Inc.
85	Cipla Limited		Exelan Pharmaceuticals Inc.
86	Cipla Limited		Goldencross Pharma Limited
87	Cipla Limited		Goldencross Pharma Limited
88	Cipla Limited		Goldencross Pharma Limited
89	Cipla Limited		Goldencross Pharma Limited
90	Cipla Limited		Goldencross Pharma Limited
91	Cipla Limited		Goldencross Pharma Limited
92	Cipla Limited		Goldencross Pharma Limited
93	Cipla Limited		Jay Precision Pharmaceuticals Private Limited
94	Cipla Limited		Medispray Laboratories Private Limited
95	Cipla Limited		Medispray Laboratories Private Limited
96	Cipla Limited		Medispray Laboratories Private Limited
97	Cipla Limited		Medispray Laboratories Private Limited
98	Cipla Limited		Medispray Laboratories Private Limited
99	Cipla Limited		Medispray Laboratories Private Limited
100	Cipla Limited		Medispray Laboratories Private Limited
101	Cipla Limited		Medispray Laboratories Private Limited
102	Cipla Limited		Meditab Specialities Limited
103	Cipla Limited		Meditab Specialities Limited
104	Cipla Limited		Meditab Specialities Limited
105	Cipla Limited		Meditab Specialities Limited
106	Cipla Limited		Meditab Specialities Limited
107	Cipla Limited		Meditab Specialities Limited
108	Cipla Limited		Medpro Pharamaceutica (Pty) Limited
109	Cipla Limited		Cipla Medpro South Africa
			(Pty) Limited
110	Cipla Limited		Medpro Pharamaceutica (Pty) Limited
111	Cipla Limited		Medpro Pharamaceutica (Pty) Limited
112	Cipla Limited		Medpro Pharamaceutica (Pty) Limited
113	Cipla Limited		Medpro Pharamaceutica (Pty) Limited
114	Cipla Limited		Medpro Pharamaceutica (Pty) Limited
115	Cipla Limited		Sitec Labs Limited
116	Cipla Limited		Sitec Labs Limited
117	Cipla Limited		Sitec Labs Limited
118	Cipla Limited		Sitec Labs Limited
119	Cipla Limited		Sitec Labs Limited
120	Cipla Limited		Sitec Labs Limited
121	Cipla Limited		Sitec Labs Limited
122	Cipla Limited		Sitec Labs Limited
123	Cipla Limited		Stempeutics Research Private Limited
124	Cipla Limited		Stempeutics Research Private Limited
125	Cipla Limited		Stempeutics Research Private Limited
126	Cipla Limited		Stempeutics Research Private Limited

Relationship of the counterparty	Type of related party transaction

with the listed entity or its
subsidiary
Holding- Subsidiary	Any other transaction
Holding- Subsidiary	Any other transaction
Holding- Subsidiary	Sale of fixed assets
Holding- Subsidiary	Sale of goods or services
Holding- Subsidiary	Purchase of goods or services
Holding- Subsidiary	Sale of goods or services
Holding- Subsidiary	Any other transaction
Holding- Subsidiary	Any other transaction
Holding- Subsidiary	Any other transaction
Holding- Subsidiary	Sale of goods or services
Holding- Subsidiary	Any other transaction
Holding- Subsidiary	Sale of goods or services
Holding- Subsidiary	Interest received
Holding- Subsidiary	Purchase of goods or services
Holding- Subsidiary	Any other transaction
Holding- Subsidiary	Any other transaction
Holding- Subsidiary	Any other transaction
Holding- Subsidiary	Sale of goods or services
Holding- Subsidiary	Sale of goods or services
Holding- Subsidiary	Any other transaction
Associate	Any other transaction
Related party of subsidiary	Sale of goods or services
Holding- Subsidiary	Any other transaction
Holding- Subsidiary	Sale of goods or services
Holding- Subsidiary	Sale of goods or services
Holding- Subsidiary	Any other transaction
Holding- Subsidiary	Any other transaction
Holding- Subsidiary	Purchase of fixed assets
Holding- Subsidiary	Purchase of goods or services
Holding- Subsidiary	Any other transaction
Holding- Subsidiary	Sale of fixed assets
Holding- Subsidiary	Sale of goods or services
Holding- Subsidiary	Sale of goods or services
Holding- Subsidiary	Purchase of goods or services
Holding- Subsidiary	Any other transaction
Holding- Subsidiary	Any other transaction
Holding- Subsidiary	Purchase of goods or services
Holding- Subsidiary	Any other transaction
Holding- Subsidiary	Any other transaction
Holding- Subsidiary	Sale of fixed assets
Holding- Subsidiary	Sale of goods or services
Holding- Subsidiary	Sale of goods or services
Holding- Subsidiary	Any other transaction
Holding- Subsidiary	Purchase of goods or services
Holding- Subsidiary	Any other transaction
Holding- Subsidiary	Sale of fixed assets
Holding- Subsidiary	Sale of goods or services
Holding- Subsidiary	Sale of goods or services
Holding- Subsidiary	Any other transaction
Holding- Subsidiary	Loan
Holding- Subsidiary	Any other transaction
Holding- Subsidiary	Any other transaction
Holding- Subsidiary	Sale of goods or services
Holding- Subsidiary	Sale of goods or services
Holding- Subsidiary	Any other transaction
Holding- Subsidiary	Interest received
Holding- Subsidiary	Loan
Holding- Subsidiary	Any other transaction
Holding- Subsidiary	Any other transaction
Holding- Subsidiary	Sale of fixed assets
Holding- Subsidiary	Sale of goods or services
Holding- Subsidiary	Sale of goods or services
Holding- Subsidiary	Any other transaction
Associate	Purchase of goods or services
Associate	Any other transaction
Associate	Any other transaction
Associate	Any other transaction

Details of other related party

transaction

Rent Received

Royalty Income

Testing and Analysis Charges Paid

Reimbursement Charges

Received

Rent Paid

Royalty Income

Reimbursement Charges Paid

Reimbursement Charges

Received

Royalty Income

Reimbursement Charges Paid

Electricity Charges Paid

Reimbursement Charges Received

Reimbursement Charges

Received

Processing Charges Paid

Reimbursement Charges Received

Processing Charges Paid Processing Charges Received

Reimbursement Charges Paid

Reimbursement Charges Received

Processing Charges Paid

Reimbursement Charges Received

Freight Charges Received

Reimbursement Charges Paid

Reimbursement Charges Received

Gurantee Commission

Received

Reimbursement Charges Paid

Reimbursement Charges Received

Testing and Analysis Charges Paid

Reimbursement Charges Paid

Payment of license fees Availing of carrying & forwarding services

			In case monies are	In case any financial indebtedness is incurred to
			due to either party as	make or give loans, inter-corporate deposits,
			a result of the	advances or investments
Value of the related party	Remarks on approval	Value of transaction			Nature of			Nature (loan/
transaction as approved	during the reporting			Details of
by the audit committee	by audit committee	period	Opening	Closing	indebtedness		advance/
	(loan/ issuance of	other	Cost Tenure	intercorporate
			balance	balance
			debt/ any other	indebtedness		deposit/

					etc.)			investment )
2.00	Approved	0.67	-	-
15.00	Approved	2.52	-	-
10.00	Approved	1.61	-	-
60.00	Approved	13.89	-	-
30.00	Approved	6.14	-	-
30.00	Approved	2.51	-	-
30.00	Approved	0.02	-	-
10.50	Approved	0.02	-	-
5.00	Approved	0.16	-	-
5.00	Approved	0.08	-	-
25.00	Approved	2.48	-	-
55.00	Approved	16.23	-	-
32.08	Approved	32.08	-	-
10.00	Approved	0.49	-	-
275.00	Approved	105.73	-	-
40.00	Approved	12.25	-	-
2,000.00	Approved	918.27	-	-
2,500.00	Approved	870.35	-	-
5.00	Approved	3.49	-	-
127.06	Approved	127.06	-	-
11.00	Approved	4.20	-	-
50.00	Approved	11.78	-	-
1.00	Approved	0.03	-	-
170.00	Approved	17.79	-	-
2.00	Approved	0.03	-	-
15.00	Approved	6.06	-	-
80.00	Approved	33.72	-	-
25.00	Approved	0.00	-	-
140.00	Approved	25.05	-	-
5.00	Approved	0.21	-	-
25.00	Approved	0.00	-	-
55.00	Approved	0.54	-	-
5.00	Approved	0.21	-	-
200.00	Approved	66.95	-	-
70.00	Approved	26.59	-	-
10.00	Approved	2.20	-	-
365.00	Approved	141.32	-	-
10.00	Approved	0.23	-	-
2.00	Approved	0.31	-	-
25.00	Approved	0.33	-	-
65.00	Approved	23.23	-	-
5.00	Approved	0.13	-	-
40.00	Approved	11.12	-	-
45.00	Approved	3.78	-	-
5.00	Approved	0.07	-	-
25.00	Approved	0.15	-	-
45.00	Approved	0.90	-	-
5.00	Approved	0.08	-	-
1.00	Approved	0.01	-	-
933.22	Approved	933.22	-	-
1.00	Approved	0.76	-	-
7.00	Approved	2.42	-	-
660.00	Approved	226.02	-	-
6.00	Approved	4.77	-	-
1.00	Approved	0.15	-	-
0.17	Approved	0.17	-	-
45.00	Approved	2.00	-	-
5.00	Approved	4.63	-	-
10.00	Approved	0.05	-	-
10.00	Approved	0.44	-	-
20.00	Approved	0.43	-	-
2.00	Approved	0.49	-	-
140.00	Approved	68.25	-	-
8.50	Approved	1.37	-	-
2.50	Approved	0.32	-	-
2.50	Approved	2.00	-	-
1.50	Approved	0.19	-	-

Details of the loans, inter-corporate deposits, advances or investments
			Purpose for which the funds Notes
Interest Rate (%)	Tenure	Secured/ unsecured	will be utilised by the
ultimate recipient of funds

(end usage)

	Details of the party (listed entity /subsidiary)	Details of the counterparty
	entering into the transaction
Sr No.

	Name	PAN	Name	PAN
127	Cipla Limited		Cipla Limited Employees Gratuity Fund
128	Cipla Limited		AMP Energy Green Eleven Private Limited
129	Cipla Limited		AMPSolar Power Systems Private Limited
130	Cipla Limited		Jay Precision Products (India) Private Limited
131	Cipla Limited		Jay Precision Products (India) Private Limited
132	Cipla Limited		Cipla Australia Pty. Ltd.
133	Cipla Limited		Cipla Australia Pty. Ltd.
134	Cipla Limited		Cipla Australia Pty. Ltd.
135	Cipla Limited		Cipla Australia Pty. Ltd.
136	Cipla Limited		Cipla Australia Pty. Ltd.
137	Cipla Limited		Cipla Brasil lmportadora E Distribuidora De
			Medicamentos Ltda.
138	Cipla Limited		Cipla Brasil lmportadora E Distribuidora De
			Medicamentos Ltda.
139	Cipla Limited		Cipla Brasil lmportadora E Distribuidora De
			Medicamentos Ltda.
140	Cipla Limited		Cipla (China) Pharmaceutical Co Ltd
141	Cipla Limited		Cipla (China) Pharmaceutical Co Ltd
142	Cipla Limited		Cipla Maroc S.A.
143	Cipla Limited		Cipla Maroc S.A.
144	Cipla Limited		Cipla Maroc S.A.
145	Cipla Limited		Cipla Maroc S.A.
146	Cipla Limited		Cipla Technologies LLC
147	Cipla Limited		Cipla Technologies LLC
148	Cipla Limited		Cipla Therapeutics Inc.
149	Cipla Limited		Cipla Therapeutics Inc.
150	Cipla Limited		GoApptiv Private Limited
151	Cipla Limited		GoApptiv Private Limited
152	Cipla Limited		GoApptiv Private Limited
153	Cipla Limited		GoApptiv Private Limited
154	Cipla Limited		Invagen Pharmaceuticals Inc.
155	Cipla Limited		Invagen Pharmaceuticals Inc.
156	Cipla Limited		Invagen Pharmaceuticals Inc.
157	Cipla Limited		Invagen Pharmaceuticals Inc.
158	Cipla Limited		Invagen Pharmaceuticals Inc.
159	Cipla Limited		Invagen Pharmaceuticals Inc.
160	Cipla Limited		Mirren (Pty) Limited
161	Cipla Limited		Mirren (Pty) Limited
162	Cipla Limited		Mirren (Pty) Limited
163	Cipla Limited		Mirren (Pty) Limited
164	Cipla Limited		Sekhmet Technologies Private Limited
165	Cipla Limited		Jay Precision Products (India) Private Limited
166	Cipla Limited		Meditab Specialities Limited
167	Cipla Limited		Medispray Laboratories Private Limited
168	Cipla Limited		Goldencross Pharma Limited
169	Cipla Limited		Sitec Labs Limited
170	Cipla Limited		Cipla Medpro South Africa
			(Pty) Limited
171	Cipla Limited		Cipla Select (Pty) Limited
172	Cipla Limited		InvaGen Pharmaceuticals Inc.
173	Cipla Limited		Exelan Pharmaceuticals Inc.
174	Cipla Limited		Cipla Malaysia Sdn. Bhd.
175	Cipla Limited		Cipla Australia Pty. Ltd.
176	Cipla Limited		Cipla Brasil Importadora E Distribuidora De
177	Cipla Limited		Cipla Europe NV
178	Cipla Limited		Cipla Holding B.V.
179	Cipla Limited		Cipla (China) Pharmaceutical Co Ltd
180	Cipla Limited		Cipla (EU) Limited
181	Cipla Limited		Sitec Labs Limited
182	Cipla Limited		Cipla Health Limited
183	Cipla Limited		Cipla Pharma and Life Sciences Limited
184	Cipla Limited		Cipla Medpro South Africa
			(Pty) Limited
185	Cipla Limited		Cipla Kenya Limited
186	Cipla Limited		Cipla USA Inc.
187	Cipla Limited		Cipla USA Inc.
188	Cipla Limited		Meditab Specialities Limited
189	Cipla Limited		Cipla Pharmaceuticals Limited
190	Cipla Limited		Cipla Digital Health Limited
191	Cipla Limited		Cipla Health Limited
192	Cipla Limited		Medpro Pharamaceutica (Pty) Limited
193	Cipla Limited		Cipla Medpro Manufacturing (Pty) Limited
194	Cipla Limited		Cipla Technologies LLC

Relationship of the counterparty

with the listed entity or its

subsidiary

Post Employment Benefit Trust

Associate

Related party of subsidiary

Holding- Subsidiary

Associate

Holding- Subsidiary

Company in which a director or manager or his relative is a member or director

Holding- Subsidiary

Type of related party transaction

Any other transaction

Purchase of fixed assets

Purchase of goods or services

Any other transaction

Sale of goods or services Purchase of goods or services Sale of goods or services Any other transaction

Any other transaction

Sale of goods or services

Any other transaction

Purchase of goods or services Any other transaction

Any other transaction

Sale of goods or services

Any other transaction

Sale of goods or services

Any other transaction

Sale of goods or services Interest received

Sale of goods or services Purchase of goods or services Investment

Purchase of goods or services Any other transaction

Any other transaction

Sale of fixed assets

Sale of goods or services

Any other transaction

Sale of goods or services Sale of goods or services Sale of fixed assets Purchase of goods or services

Any other transaction

Loan

Any other transaction

Loan

Any other transaction

Details of other related party

transaction

Contribution to Gratuity Fund

Electricity Charges Paid

Reimbursement Charges Paid

Reimbursement Charges Received

Reimbursement Charges Paid

Reimbursement Charges Received

Reimbursement Charges Paid

Reimbursement Charges

Received

Royalty Income

Reimbursement Charges Received

Reimbursement Charges Paid

Reimbursement Charges Received

Trade and Other payable

Trade and Other payable Trade and Other payable Trade and Other payable Trade and Other payable Trade and Other receivable

Trade and Other receivable Trade and Other payable Trade and Other payable Trade and Other payable Trade and Other payable Trade and Other payable

Trade and Other payable Trade and Other payable Trade and Other payable Trade and Other payable

Trade and Other payable Trade and Other receivable

Capital Advance

Trade and Other receivable Trade and Other receivable Trade and Other receivable Trade and Other receivable Trade and Other receivable

Trade and Other receivable

			In case monies are
			due to either party as
			a result of the
Value of the related party	Remarks on approval	Value of transaction
transaction as approved	by audit committee	during the reporting
by the audit committee	period	Opening	Closing

			balance	balance
55.00	Approved	10.00	-	-
12.00	Approved	4.62	-	-
20.00	Approved	8.49	-	-
40.00	Approved	12.38	-	-
40.00	Approved	0.04	-	-
22.43	Approved	22.43	-	-
1.00	Approved	0.12	-	-
85.00	Approved	23.85	-	-
30.00	Approved	4.58	-	-
1.00	Approved	0.47	-	-
50.00	Approved	13.37	-	-
1.00	Approved	0.03	-	-
50.00	Approved	0.99	-	-
6.00	Approved	0.13	-	-
22.00	Approved	4.35	-	-
2.00	Approved	0.30	-	-
1.00	Approved	0.03	-	-
100.00	Approved	16.33	-	-
1.00	Approved	0.17	-	-
5.00	Approved	0.41	-	-
6.00	Approved	0.06	-	-
10.00	Approved	1.35	-	-
1.00	Approved	0.07	-	-
1.00	Approved	0.01	-	-
12.00	Approved	0.47	-	-
50.00	Approved	15.06	-	-
60.00	Approved	42.00	-	-
30.00	Approved	0.10	-	-
15.00	Approved	11.09	-	-
5.00	Approved	3.29	-	-
20.00	Approved	7.08	-	-
60.00	Approved	7.50	-	-
2.00	Approved	1.46	-	-
1.00	Approved	0.02	-	-
10.00	Approved	0.01	-	-
1.29	Approved	1.29	-	-
15.00	Approved	0.43	-	-
15.00	Approved	3.59	-	-
-	Not applicable	-	51.80	16.59
-	Not applicable	-	5.47	5.09
-	Not applicable	-	32.42	22.20
-	Not applicable	-	17.44	11.62
-	Not applicable	-	12.16	9.29
-	Not applicable	-	17.24	21.22
-	Not applicable	-	13.10	19.65
-	Not applicable	-	-11.24	7.59
-	Not applicable	-	22.08	17.05
-	Not applicable	-	3.77	2.23
-	Not applicable	-	7.99	32.53
-	Not applicable	-	6.56	5.78
-	Not applicable	-	51.25	68.52
-	Not applicable	-	2.47	4.90
-	Not applicable	-	9.19	9.49
-	Not applicable	-	-1.02	30.42
-		-	3.00	5.00
-		-	65.20	50.20
-		-	-	199.35
-		-	-	917.70
-	Not applicable	-	16.79	18.52
-	Not applicable	-	738.02	837.53
-		-	1,023.13	1,011.18
-	Not applicable	-	55.74	55.74
-	Not applicable	-	-0.02	0.02
-	Not applicable	-	1.73	2.55
-	Not applicable	-	72.85	11.24
-	Not applicable	-	230.44	237.78
-	Not applicable	-	6.00	5.23
-	Not applicable	-	0.10	0.15

entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.

In case any financial indebtedness is incurred to

make or give loans, inter-corporate deposits,Details of the loans, inter-corporate deposits, advances or investments advances or investments

Nature of		Nature (loan/				Purpose for which the funds Notes
indebtedness	Details of	advance/
			will be utilised by the
(loan/ issuance of	other	Cost Tenure intercorporate	Interest Rate (%)	Tenure	Secured/ unsecured
ultimate recipient of funds
debt/ any other	indebtedness	deposit/
			(end usage)
etc.)		investment )

Loan	6.88%	5 Years	Unsecured	Working Capital
Loan	7.35%	7 Years	Unsecured	Working Capital
Loan	7.50%	2-5 years	Unsecured	Working Capital
Loan	250 bps higher than 3 months JIBAR	Repayament starts with 31st	Unsecured	Working Capital and capital
	rate capped at the prime lending rate	March 2026 to Oct 2029		expenditure
	in South Africa
Loan	Term SOFR+140 bps	1 year	Unsecured	Working Capital

entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.

Details of the party (listed entity /subsidiary)	Details of the counterparty
entering into the transaction

Sr No.

Type of related party transaction

Details of other related party

		In case monies are	In case any financial indebtedness is incurred to
		due to either party as	make or give loans, inter-corporate deposits,
		a result of the	advances or investments
Value of the related party	Remarks on approval	Value of transaction	Nature of	Nature (loan/
transaction as approved	during the reporting

Details of the loans, inter-corporate deposits, advances or investments

Purpose for which the funds Notes

	Name	PAN	Name	PAN
195	Cipla Limited		Cipla Colombia SAS
196	Cipla Limited		Cipla Therapeutics Inc.
197	Cipla Limited		Aspergen Inc.
198	Cipla Limited		Breathe Free Lanka (Private) Limited
199	Cipla Limited		Cipla Maroc SA
200	Cipla Limited		Cipla Gulf FZ LLC
201	Cipla Limited		Cipla (Jiangsu) Pharmaceutical Co., Ltd
202	Cipla Limited		Cipla Pharma and Life Sciences Limited
203	Cipla Limited		Mirren (Pty) Limited
204	Cipla Limited		A S Kumar
205	Cipla Limited		Abhayan Jawaharlal
206	Cipla Limited		Achin Gupta
207	Cipla Limited		Akshaya Vaibhav Ambeskar
208	Cipla Limited		Anand Agarwal
209	Cipla Limited		Anil Kumar Choudhary
210	Cipla Limited		Animesh Mohanlal Jain
211	Cipla Limited		Anisha N Udeshi
212	Cipla Limited		Ankit Kirit Gudhka
213	Cipla Limited		Arjun Mukherjee
214	Cipla Limited		Atul Yeshwant Sant
215	Cipla Limited		Bijay Kumar Temani
216	Cipla Limited		Chirag Kamal Hotchandani
217	Cipla Limited		Deepali Choudhary
218	Cipla Limited		Deepraj Manohar Desai
219	Cipla Limited		Dinesh Ramniranjan Jain
220	Cipla Limited		Geena V Malhotra
221	Cipla Limited		Girish Brijmohan Zamwar
222	Cipla Limited		Jaideep A Gogtay
223	Cipla Limited		Jinesh Chauhan
224	Cipla Limited		Kaustubh Deshpande
225	Cipla Limited		Kushagra Mathur
226	Cipla Limited		Mandar Mahendra Kurghode
227	Cipla Limited		Nakul Arora
228	Cipla Limited		Naveen Bansal
229	Cipla Limited		Navya Sri Swathi Yerramilli
230	Cipla Limited		Pantha Milan Kundu
231	Cipla Limited		Patsy Jeffery
232	Cipla Limited		Pavankumar Yadav
233	Cipla Limited		Piyush Salot
234	Cipla Limited		Rahul Verma
235	Cipla Limited		Sanjay Kumar Mishra
236	Cipla Limited		Shrinivas Madhukar Purandare
237	Cipla Limited		Siddharth Rajesh Jain
238	Cipla Limited		Sunil Gupta
239	Cipla Limited		Swapn Malpani
240	Cipla Limited		Ujwal Prakash Shendre
241	Cipla Limited		Vaibhav Pravin Ambeskar
242	Cipla Limited		Umang Vohra
243	Cipla Limited		Samina Hamied
244	Cipla Limited		Rajendra Chopra
245	Cipla Limited		Ashish Adukia
246	Cipla Limited		Dr Y K Hamied
247	Cipla Limited		Mr M K Hamied
248	Cipla Limited		Mr S Radhakrishnan
249	Cipla Limited		Dr Peter Mugyenyi
250	Cipla Limited		Mr. Ashok Sinha
251	Cipla Limited		Mr Adil Zainulbhai
252	Cipla Limited		Ms Punita Lal
253	Cipla Limited		Mr Robert Stewart
254	Cipla Limited		Mr P R Ramesh
255	Cipla Limited		Dr Mandar Vaidya
256	Cipla Limited		GoApptiv Private Limited
257	Cipla Limited		Sekhmet Technologies Private Limited
258	Cipla Limited		Stempeutics Research Private Limited
259	Cipla Limited		AMP Energy Green Eleven Private Limited

Relationship of the counterpartytransaction with the listed entity or its

subsidiary

Holding- Subsidiary	Any other transaction	Trade and Other receivable
Holding- Subsidiary	Any other transaction	Trade and Other receivable
Holding- Subsidiary	Any other transaction	Trade and Other receivable
Holding- Subsidiary	Any other transaction	Trade and Other receivable
Holding- Subsidiary	Any other transaction	Trade and Other receivable
Holding- Subsidiary	Any other transaction	Trade and Other receivable
Holding- Subsidiary	Any other transaction	Trade and Other receivable
Holding- Subsidiary	Any other transaction	Trade and Other receivable
Holding- Subsidiary	Any other transaction	Trade and Other receivable
Director of subsidiary	Any other transaction	Professional Fees
Director of subsidiary	Remuneration
Director of Subsidairy	Remuneration
KMP of subsidiary	Remuneration
Director of subsidiary	Remuneration
KMP of subsidiary	Remuneration
KMP of subsidiary	Remuneration
Director of subsidiary	Remuneration
Director of subsidiary	Remuneration
KMP of subsidiary	Remuneration
Director of subsidiary	Remuneration
Director of subsidiary	Remuneration
KMP of subsidiary	Remuneration
Director of subsidiary	Remuneration
KMP of subsidiary	Remuneration
Director of subsidiary	Remuneration
Director of subsidiary	Remuneration
Director and KMP of subsidiary	Remuneration
Director of subsidiary	Remuneration
KMP of subsidiary	Remuneration
Director of subsidiary	Remuneration
Director of subsidiary	Remuneration
KMP of subsidiary	Remuneration
Director of subsidiary	Remuneration
Director of subsidiary	Remuneration
KMP of subsidiary	Remuneration
KMP of subsidiary	Remuneration
Director of subsidiary	Remuneration
KMP of subsidiary	Remuneration
KMP of subsidiary	Remuneration
KMP of subsidiary	Remuneration
KMP of subsidiary	Remuneration
Director of subsidiary	Remuneration
KMP of subsidiary	Remuneration
Director of subsidiary	Remuneration
Director of subsidiary	Remuneration
KMP of subsidiary	Remuneration
Relative of KMP	Remuneration
Key Managerial Personnel	Remuneration
Key Managerial Personnel	Remuneration
Key Managerial Personnel	Remuneration
Key Managerial Personnel	Remuneration
Non-executive Chairman	Any other transaction	Commission and other benefits
Non-executiveVice-Chairman	Any other transaction	Commission and other benefits
Non-executive director	Any other transaction	Commission and other benefits
Non-executive Independent	Any other transaction	Commission and other benefits
director
Non-executive Independent	Any other transaction	Commission and other benefits
director
Non-executive Independent	Any other transaction	Commission and other benefits
director
Non-executive Independent	Any other transaction	Commission and other benefits
director
Non-executive Independent	Any other transaction	Commission and other benefits
director
Non-executive Independent	Any other transaction	Commission and other benefits
director
Non-executive Independent	Any other transaction	Commission and other benefits
director
Associate	Any other transaction	Trade and Other payable
Company in which a director or	Any other transaction	Trade and Other payable
manager or his relative is a
member or director
Associate	Any other transaction	Trade and Other payable
Associate	Any other transaction	Trade and Other payable

by the audit committee	by audit committee	period	Opening	Closing	indebtedness	Details of	advance/
	(loan/ issuance of	other	Cost Tenure	intercorporate
			balance	balance
			debt/ any other	indebtedness		deposit/

					etc.)		investment )
-	Not applicable	-	36.82	39.85
-	Not applicable	-	-	0.07
-	Not applicable	-	1.42	1.07
-	Not applicable	-	83.35	67.52
-	Not applicable	-	14.00	9.59
-	Not applicable	-	45.52	54.55
-	Not applicable	-	0.05	0.15
-	Not applicable	-	-4.03	27.48
-	Not applicable	-	-0.75	1.98
5.10	Approved	1.40	-	-
2.31	Approved	0.89	-	-
10.22	Approved	1.98	-	-
0.12	Approved	0.06	-	-
1.52	Approved	0.54	-	-
0.40	Approved	0.16	-	-
0.84	Approved	0.35	-	-
1.10	Approved	0.45	-	-
0.37	Approved	0.16	-	-
0.79	Approved	0.34	-	-
1.47	Approved	0.13	-	-
0.39	Approved	0.17	-	-
0.18	Approved	0.08	-	-
0.45	Approved	0.19	-	-
0.43	Approved	0.19	-	-
2.87	Approved	0.96	-	-
6.97	Approved	2.00	-	-
1.34	Approved	0.53	-	-
4.51	Approved	1.18	-	-
1.17	Approved	0.41	-	-
1.55	Approved	0.39	-	-
0.42	Approved	0.19	-	-
0.31	Approved	0.13	-	-
0.47	Approved	0.20	-	-
0.87	Approved	0.36	-	-
0.12	Approved	0.05	-	-
0.40	Approved	0.17	-	-
1.96	Approved	0.68	-	-
0.08	Approved	0.04	-	-
0.41	Approved	0.19	-	-
1.40	Approved	0.54	-	-
1.18	Approved	0.47	-	-
2.92	Approved	0.98	-	-
0.54	Approved	0.23	-	-
1.85	Approved	0.14	-	-
3.70	Approved	0.03	-	-
1.65	Approved	0.63	-	-
0.24	Approved	0.10	-	-
-	Approval as per Board	4.29	-	-
	of director or
	shareholder as
	necessary
-	Approval as per Board	4.32	-	-
	of director or
	shareholder as
	necessary
-	Approval as per Board	1.02	-	-
	of director or
	shareholder as
	necessary
-	Approval as per Board	1.85	-	-
	of director or
	shareholder as
	necessary
-		1.58	-	-
-		1.59	-	-
-		1.66	-	-
-		0.03	-	-
-		0.68	-	-
-		0.69	-	-
-		0.76	-	-
-		0.75	-	-
-		0.65	-	-
-		0.59	-	-
-	Not applicable	-	5.03	1.20
-	Not applicable	-	0.92	1.12
-	Not applicable	-	-0.02	2.64
-	Not applicable	-	0.40	0.60

Interest Rate (%)	Tenure	Secured/ unsecured	will be utilised by the
ultimate recipient of funds

(end usage)

entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.

Details of the party (listed entity /subsidiary)	Details of the counterparty
entering into the transaction

Sr No.

Type of related party transaction

Details of other related party

Value of the related party	Remarks on approval
transaction as approved

Value of transaction during the reporting

In case monies are	In case any financial indebtedness is incurred to
due to either party as	make or give loans, inter-corporate deposits,
a result of the	advances or investments
	Nature of	Nature (loan/

Details of the loans, inter-corporate deposits, advances or investments

Purpose for which the funds Notes

Name	PAN	Name	PAN
260 Cipla Limited		Cipla Foundation

Relationship of the counterpartytransaction with the listed entity or its

subsidiary

The entity over which KMP or	Any other transaction	Trade and Other receivable
relative of KMP are able to
exercise significant influence

by the audit committee	by audit committee

Not applicable

period

Opening	Closing	indebtedness	Details of	advance/
(loan/ issuance of	other	Cost Tenure intercorporate
balance	balance
debt/ any other	indebtedness	deposit/

		etc.)		investment )

0.15

Interest Rate (%)	Tenure	Secured/ unsecured	will be utilised by the
ultimate recipient of funds

(end usage)

261	Cipla Limited	AMPSolar Power Systems Private Limited	Associate	Any other transaction	Trade and Other payable	-	Not applicable	-	1.42	0.63
262	Cipla Limited	Societe Marocaine De Cooperation	Related party of subsidiary	Any other transaction	Trade and Other receivable	-	Not applicable	-	10.72	11.00
		Pharmaceutique (Cooper)
263	Cipla Limited	Clean Max Auriga Power LLP	Associate	Any other transaction	Trade and Other receivable	-	Not applicable	-	-0.39	0.01
264	Cipla Limited	Mr Adil Zainulbhai	Non-executive Independent	Any other transaction	Commission and other benefits	-		-	0.26	0.55
			director		payable
265	Cipla Limited	Mr. Ashok Sinha	Non-executive Independent	Any other transaction	Commission and other benefits	-		-	0.30	0.77
			director		payable
266	Cipla Limited	Mr M K Hamied	Non-executiveVice-Chairman	Any other transaction	Commission and other benefits	-		-	1.00	1.53
					payable
267	Cipla Limited	Dr Y K Hamied	Non-executive Chairman	Any other transaction	Commission and other benefits	-		-	1.00	1.53
					payable
268	Cipla Limited	Ms Punita Lal	Non-executive Independent	Any other transaction	Commission and other benefits	-		-	0.28	0.64
			director		payable
269	Cipla Limited	A S Kumar	Director of subsidiary	Any other transaction	Trade and Other payable	-	Not applicable	-	0.72	1.34
270	Cipla Limited	Mr S Radhakrishnan	Non-executive director	Any other transaction	Commission and other benefits	-		-	1.00	1.53
					payable
271	Cipla Limited	Dr Mandar Vaidya	Non-executive Independent	Any other transaction	Commission and other benefits	-		-	0.28	0.68
			director		payable
272	Cipla Limited	Mr P R Ramesh	Non-executive Independent	Any other transaction	Commission and other benefits	-		-	0.28	0.72
			director		payable
273	Cipla Limited	Dr Peter Mugyenyi	Non-executive Independent	Any other transaction	Commission and other benefits	-		-	0.07	0.07
			director		payable
274	Cipla Limited	Mr Robert Stewart	Non-executive Independent	Any other transaction	Commission and other benefits	-		-	0.31	0.64
			director		payable
275	Cipla Limited	Cipla Limited Employees Gratuity Fund	Post Employment Benefit Trust	Any other transaction	Payable to Gratuity Trust	-		-	3.08	86.34
276	Cipla Limited	Cipla Limited Employees Provident fund	Post Employment Benefit Trust	Any other transaction	Payable to Provident Fund	-		-	13.66	13.85
					Trust
277	Cipla Limited	Cipla Digital Health Limited	Holding- Subsidiary	Investment		20.00	Approved	6.50	-	-
278	Cipla Limited	Jay Precision Products (India) Private Limited	Related party of subsidiary	Any other transaction	Trade and Other payable	-		-	-8.24	0.18
279	Cipla Limited	Cipla Quality Chemical Industries Limited	Holding- Subsidiary	Any other transaction	Trade and Other receivable	-	Not applicable	-	30.16	-
280	Jay Precision Pharmaceuticals	Zubin Rao	Key Management Personnel of	Any other transaction	Sitting Fees/Commission and	-		0.17	-	-
	Private Limited		Subsidiary		Other Benefits
281	Jay Precision Pharmaceuticals	Zubin Rao	Key Management Personnel of	Any other transaction	Sitting Fees/Commission and	-		-	0.15	0.30
	Private Limited		Subsidiary		Other Benefits
282	Jay Precision Pharmaceuticals	Xerxes Rao	Key Management Personnel of	Any other transaction	Sitting Fees/Commission and	-		0.29	-	-
	Private Limited		Subsidiary		Other Benefits
283	Jay Precision Pharmaceuticals	Xerxes Rao	Key Management Personnel of	Any other transaction	Sitting Fees/Commission and	-		-	0.17	0.33
	Private Limited		Subsidiary		Other Benefits
284	Jay Precision Pharmaceuticals	Xerxes Rao	Key Management Personnel of	Remuneration		-		0.62	-	-
	Private Limited		Subsidiary
285	Jay Precision Pharmaceuticals	Xerxes Rao	Key Management Personnel of	Remuneration		-		-	0.06	0.06
	Private Limited		Subsidiary
286	Jay Precision Pharmaceuticals	Amrita Nautiyal	Key Management Personnel of	Any other transaction	Sitting Fees/Commission and	-		0.02	-	-
	Private Limited		Subsidiary		Other Benefits
287	Jay Precision Pharmaceuticals	Chandrashekhar Iyer	Key Management Personnel of	Any other transaction	Sitting Fees/Commission and	-		0.02	-	-
	Private Limited		Subsidiary		Other Benefits
288	Jay Precision Pharmaceuticals	Cipla Foundation	The entity over which KMP or	Any other transaction	CSR Contribution	1.00	Approved	0.42	-	-
	Private Limited		relative of KMP are able to
			exercise significant influence
289	Jay Precision Pharmaceuticals	Jay Precision Products (India) Private Limited	Private Companies in which a	Purchase of fixed assets		20.00	Approved	9.22	-	-
	Private Limited		director or manager or his
			relative is a member or director
290	Jay Precision Pharmaceuticals	Jay Precision Products (India) Private Limited	Private Companies in which a	Any other transaction	Capital Creditor	-	Not applicable	-	-6.93	4.11
	Private Limited		director or manager or his
			relative is a member or director
291	Jay Precision Pharmaceuticals	Jay Precision Products (India) Private Limited	Private Companies in which a	Any other transaction	Rent Income	1.00	Approved	0.08	-	-
	Private Limited		director or manager or his
			relative is a member or director
292	Jay Precision Pharmaceuticals	Jay Precision Products (India) Private Limited	Private Companies in which a	Sale of goods or services		1.00	Approved	0.10	-	-
	Private Limited		director or manager or his
			relative is a member or director

entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.

Details of the party (listed entity /subsidiary)

In case monies are

In case any financial indebtedness is incurred to

Details of the counterparty

due to either party as

make or give loans, inter-corporate deposits,

entering into the transaction

Sr No.

a result of the

advances or investments

Value of the related party

Value of transaction

Details of other related party

Remarks on approval

Nature of

Nature (loan/

Relationship of the counterparty

Type of related party transaction

transaction as approved

during the reporting

Details of

transaction

by the audit committee

by audit committee

period

Opening

Closing

indebtedness

advance/

Name

PAN

Name

PAN

with the listed entity or its

(loan/ issuance of

other

Cost Tenure

intercorporate

balance

subsidiary

debt/ any other

indebtedness

deposit/

etc.)

investment )

293

Jay Precision Pharmaceuticals

Jay Precision Products (India) Private Limited

Private Companies in which a

Purchase of goods or services

1.00

Approved

0.37

Private Limited

director or manager or his

relative is a member or director

294

Jay Precision Pharmaceuticals

Jay Precision Products (India) Private Limited

Private Companies in which a

Any other transaction

Trade and Other receivable

Not applicable

-0.10

0.03

Private Limited

director or manager or his

relative is a member or director

295

Jay Precision Pharmaceuticals

Medispray Laboratories Private Limited

Subsidiaries

Sale of goods or services

25.00

Approved

4.23

Private Limited

296

Jay Precision Pharmaceuticals

Medispray Laboratories Private Limited

Subsidiaries

Any other transaction

Trade and Other Receivable

Not applicable

0.39

1.66

Private Limited

297

Jay Precision Pharmaceuticals

Cipla Maroc S.A.

Subsidiaries

Any other transaction

Trade and Other Receivable

Not applicable

0.14

Private Limited

298

Medispray Laboratories Private

Meditab Specialities Limited

Subsidiaries

Any other transaction

Reimbursement Charges

2.00

Approved

0.07

Limited

received

299

Medispray Laboratories Private

Meditab Specialities Limited

Subsidiaries

Purchase of Fixed Assets

25.00

0.12

Limited

300

Medispray Laboratories Private

Cipla Maroc S.A.

Subsidiaries

Sale of goods or services

30.00

Approved

9.20

Limited

301

Medispray Laboratories Private

Cipla Maroc S.A.

Subsidiaries

Any other transaction

Trade and Other Receivable

5.54

3.60

Limited

302

Medispray Laboratories Private

Jay Precision Products (India) Private Limited

Private Companies in which a

Purchase of goods or services

5.00

Approved

0.02

Limited

director or manager or his

relative is a member or director

303

Medispray Laboratories Private

Jay Precision Products (India) Private Limited

Private Companies in which a

Any other transaction

Reimbursement Charges paid

1.00

Approved

0.00

Limited

director or manager or his

relative is a member or director

304

Medispray Laboratories Private

Jay Precision Products (India) Private Limited

Private Companies in which a

Any other transaction

Trade and Other receivable

Not applicable

-1.16

0.00

Limited

director or manager or his

relative is a member or director

305

Medispray Laboratories Private

Cipla Foundation

The entity over which KMP or

Any other transaction

CSR Contribution

2.00

Approved

0.62

Limited

relative of KMP are able to

exercise significant influence

306

Medispray Laboratories Private

The Pharmaceutical Institute (PHI)

Related party of subsidiary

Sale of goods or services

8.00

Approved

2.76

Limited

307

Medispray Laboratories Private

The Pharmaceutical Institute (PHI)

Related party of subsidiary

Any other transaction

Trade and Other receivable

Not applicable

2.19

2.55

Limited

308

Medispray Laboratories Private

Medispray Laboratories Private Limited

Post employment benefit trust

Any other transaction

Contribution during the period

1.00

Approved

-0.18

Limited

Employees Comprehensive Gratuity Scheme

309

Medispray Laboratories Private

Medispray Laboratories Private Limited

Post employment benefit trust

Any other transaction

Payable to Gratuity Trust

Not applicable

2.03

6.90

Limited

Employees Comprehensive Gratuity Scheme

310

Meditab Specialities Limited

Medispray Laboratories Private Limited

Subsidiaries

Any other transaction

Reimbursement Charges

3.00

Approved

0.02

received

311

Meditab Specialities Limited

Medispray Laboratories Private Limited

Subsidiaries

Any other transaction

Trade and Other Receivable

Not applicable

-0.00

0.05

312

Meditab Specialities Limited

Cipla Foundation

The entity over which KMP or

Any other transaction

CSR Contribution

1.00

Approved

0.05

relative of KMP are able to

exercise significant influence

313

Meditab Specialities Limited

Meditab Specialities Limited Employees

Post employment benefit trust

Any other transaction

Contribution during the period

1.00

Approved

-0.16

Comprehensive Gratuity Scheme

314

Meditab Specialities Limited

Meditab Specialities Limited Employees

Post employment benefit trust

Any other transaction

Payable to Gratuity Trust

Not applicable

0.64

0.85

Comprehensive Gratuity Scheme

315

Sitec Labs Limited

Cipla (Jiangsu) Pharmaceutical Co. Limited

Subsidiaries

Any other transaction

Testing and Analysis Charges

12.00

Approved

0.17

Received

316

Sitec Labs Limited

Cipla (Jiangsu) Pharmaceutical Co. Limited

Subsidiaries

Any other transaction

Trade and Other Receivable

Not applicable

1.39

0.48

317

Sitec Labs Limited

Cipla USA Inc.

Subsidiaries

Any other transaction

Testing and Analysis Charges

5.00

Approved

0.28

Received

318

Sitec Labs Limited

Cipla USA Inc.

Subsidiaries

Any other transaction

Trade and Other Receivable

Not applicable

-0.01

0.33

319

Sitec Labs Limited

Medispray Laboratories Private Limited

Subsidiaries

Any other transaction

Testing and Analysis Charges

5.00

Approved

0.01

Received

320

Sitec Labs Limited

Medispray Laboratories Private Limited

Subsidiaries

Any other transaction

Trade and Other Receivable

Not applicable

0.02

321

Sitec Labs Limited

Meditab Specialities Limited

Subsidiaries

Any other transaction

Testing and Analysis Charges

5.00

Approved

0.00

Received

322

Sitec Labs Limited

Meditab Specialities Limited

Subsidiaries

Any other transaction

Trade and Other Receivable

Not applicable

0.00

323

Sitec Labs Limited

Cipla Health Limited

Subsidiaries

Any other transaction

Trade and Other Receivable

Not applicable

0.02

0.00

324

Sitec Labs Limited

Invagen Pharmaceuticals Inc.

Subsidiaries

Any other transaction

Testing and Analysis Charges

Not applicable

0.37

Received

325

Sitec Labs Limited

Invagen Pharmaceuticals Inc.

Subsidiaries

Any other transaction

Trade and Other Receivable

1.65

0.41

326

Sitec Labs Limited

Krishnan Iyer

Key Management Personnel of

Remuneration

0.58

Subsidiary

Details of the loans, inter-corporate deposits, advances or investments
			Purpose for which the funds Notes
Interest Rate (%)	Tenure	Secured/ unsecured	will be utilised by the
ultimate recipient of funds

(end usage)

entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.

Details of the party (listed entity /subsidiary)

In case monies are

In case any financial indebtedness is incurred to

Details of the counterparty

due to either party as

make or give loans, inter-corporate deposits,

entering into the transaction

Sr No.

a result of the

advances or investments

Value of the related party

Value of transaction

Details of other related party

Remarks on approval

Nature of

Nature (loan/

Relationship of the counterparty

Type of related party transaction

transaction as approved

during the reporting

Details of

transaction

by the audit committee

by audit committee

period

Opening

Closing

indebtedness

advance/

Name

PAN

Name

PAN

with the listed entity or its

(loan/ issuance of

other

Cost Tenure

intercorporate

balance

subsidiary

debt/ any other

indebtedness

deposit/

etc.)

investment )

327

Sitec Labs Limited

Sitec Labs Private Limited Employees

Post employment benefit trust

Any other transaction

Payable to Gratuity Trust

Not applicable

1.47

4.27

Comprehensive Gratuity Scheme

328

Sitec Labs Limited

Cipla Foundation

The entity over which KMP or

Any other transaction

CSR Contribution

1.00

Approved

0.17

relative of KMP are able to

exercise significant influence

329

Cipla Digital Health Limited

Ashish Vig

Key Management Personnel of

Remuneration

0.87

Subsidiary

330

Cipla Australia Pty Ltd

Cipla Gulf FZ LLC

Subsidiary

Any other transaction

Reimbursement Charges

Not applicable

1.52

received

331

Cipla (Jiangsu) Pharmaceutical

Ijaj Khalif

Key Management Personnel of

Remuneration

0.68

Co. Limited

Subsidiary

332

Cipla Health Limited

GoApptiv Private Limited

Associate

Any other transaction

Purchase Return

4.00

0.17

333

Cipla Health Limited

GoApptiv Private Limited

Associate

Any other transaction

Trade and Other payable

Not applicable

0.98

334

Cipla Health Limited

Postcard media

The entity over which KMP or

Purchase of goods or services

0.15

Approved

0.04

relative of KMP are able to

exercise significant influence

335

Cipla Health Limited

Postcard media

The entity over which KMP or

Any other transaction

Trade and Other payable

Not applicable

0.02

relative of KMP are able to

exercise significant influence

336

Cipla Health Limited

Cipla Pharma and Life Sciences Limited

Subsidiaries

Any other transaction

Reimbursement Charges

2.47

Approved

2.47

received

337

Cipla Health Limited

Cipla Pharma and Life Sciences Limited

Subsidiaries

Any other transaction

Trade and Other Receivable

Not applicable

2.47

338

Cipla Health Limited

Shivam Puri

Key Management Personnel of

Remuneration

1.22

Subsidiary

339

Cipla Health Limited

Sukhdev Jaluka

Key Management Personnel of

Remuneration

0.44

Subsidiary

340

Cipla Health Limited

Chandrashekhar Iyer

Key Management Personnel of

Any other transaction

Sitting Fees/Commission and

0.02

Subsidiary

Other Benefits

341

Cipla Health Limited

Amrita Nautiyal

Key Management Personnel of

Any other transaction

Sitting Fees/Commission and

0.02

Subsidiary

Other Benefits

342

Cipla Health Limited

Cipla Health Limited Employees Gratuity

Post employment benefit trust

Any other transaction

Payable to Gratuity Trust

Not applicable

2.07

1.63

Scheme

343

Cipla Health Limited

Cipla Health Limited Employees Gratuity

Post employment benefit trust

Any other transaction

Contribution during the period

2.00

Approved

2.00

Scheme

344

Goldencross Pharma Limited

Cipla Health Limited

Subsidiaries

Sale of goods or services

30.00

Approved

6.42

345

Goldencross Pharma Limited

Cipla Health Limited

Subsidiaries

Any other transaction

Trade and Other Receivable

Not applicable

0.41

1.83

346

Cipla Pharma and Life Sciences

Cipla Foundation

The entity over which KMP or

Any other transaction

CSR Contribution

1.00

Approved

0.01

Limited

relative of KMP are able to

exercise significant influence

347

Goldencross Pharma Limited

Cipla Foundation

The entity over which KMP or

Any other transaction

CSR Contribution

1.00

Approved

0.15

relative of KMP are able to

exercise significant influence

348

Goldencross Pharma Limited

Goldencross Pharma Ltd Employees Group

Post employment benefit trust

Any other transaction

Contribution during the period

1.00

Approved

-0.41

Gratuity Fund

349

Goldencross Pharma Limited

Goldencross Pharma Ltd Employees Group

Post employment benefit trust

Any other transaction

Payable to Gratuity Trust

0.71

2.11

Gratuity Fund

350

Cipla Pharma and Life Sciences

Meditab Specialities Limited

Subsidiaries

Any other transaction

Testing and Analysis charges

1.00

Approved

-0.02

Limited

received

351

Cipla Pharma and Life Sciences

Meditab Specialities Limited

Subsidiaries

Any other transaction

Trade and Other Receivable

Not applicable

0.02

Limited

352

Meditab Specialities Limited

Meditab holdings

Subsidiaries

Any other transaction

Buy back of shares

191.11

Approved

191.11

353

Cipla Pharma and Life Sciences

Cipla Pharma and Life Sciences Limited

Post employment benefit trust

Any other transaction

Payable to Gratuity Trust

0.00

0.06

Limited

Employees Gratuity Fund

354

Cipla Pharma and Life Sciences

GoApptiv Private Limited

Associate

Any other transaction

Professional Fees

1.00

Approved

0.02

Limited

355

Jay Precision Pharmaceuticals

Jay Precision Pharmaceuticals Group Gratuity

Post employment benefit trust

Any other transaction

Contribution during the period

Not applicable

0.77

Private Limited

Fund

356

Jay Precision Pharmaceuticals

Jay Precision Pharmaceuticals Group Gratuity

Post employment benefit trust

Any other transaction

Payable to Gratuity Trust

Not applicable

0.02

Private Limited

Fund

357

Medpro Pharmaceutica Pty Ltd

Cipla Select Pty Ltd

Subsidiary

Sale of goods or services

10.00

Approved

0.10

358

Medpro Pharmaceutica Pty Ltd

Cipla Select Pty Ltd

Subsidiary

Any other transaction

Trade and Other receivable

Not applicable

1.08

0.04

359

Cipla Medpro Distribution

Medpro Pharmaceutica Pty Ltd

Subsidiary

Any other transaction

Reimbursement charges

100.00

Approved

30.34

Centre Pty Ltd

received

360

Cipla-Medpro Pty Ltd

Medpro Pharmaceutica Pty Ltd

Subsidiary

Any other transaction

Royalty income

30.00

Approved

9.83

361

Cipla-Medpro Pty Ltd

Cipla Select Pty Ltd

Subsidiary

Any other transaction

Trade and Other receivable

Not applicable

3.06

3.53

362

Cipla-Medpro Pty Ltd

Cipla Select Pty Ltd

Subsidiary

Any other transaction

Royalty income

6.00

Approved

0.44

363

Cipla Medpro Manufacturing

Medpro Pharmaceutica Pty Ltd

Subsidiary

Any other transaction

Trade and Other receivable

Not applicable

47.05

160.27

Pty Ltd

364

Cipla Medpro Manufacturing

Medpro Pharmaceutica Pty Ltd

Subsidiary

Sale of goods or services

500.00

Approved

209.71

Pty Ltd

365

Mirren Pty Ltd

Medpro Pharmaceutica Pty Ltd

Subsidiary

Sale of goods or services

150.00

Approved

46.34

366

Cipla Medpro Manufacturing

Cipla Select Pty Ltd

Subsidiary

Any other transaction

Trade and Other receivable

Not applicable

0.38

6.29

Pty Ltd

367

Cipla Medpro Manufacturing

Cipla Select Pty Ltd

Subsidiary

Sale of goods or services

10.00

Approved

4.87

Pty Ltd

368

Cipla Medpro Manufacturing

Cipla Foundation (South Africa)

Entities over which the company Any other transaction

CSR Contribution

15.00

Approved

4.46

Pty Ltd

is able to exercise significant

influence/Control

369

Cipla Medpro South Africa Pty

Brandmed (Pty) Limited

Associate

Any other transaction

Loan given

16.34

16.98

Loan

Ltd

Details of the loans, inter-corporate deposits, advances or investments
			Purpose for which the funds Notes
Interest Rate (%)	Tenure	Secured/ unsecured	will be utilised by the
ultimate recipient of funds

(end usage)

South African prime rate less 1.75% Repayment to start from 31	Unsecured	Working capital
March 2025 to 31 March 2028		requirement

Details of the party (listed entity /subsidiary)		Details of the counterparty
entering into the transaction

Sr No.
Name	PAN	Name	PAN

Relationship of the counterparty

with the listed entity or its

subsidiary

Type of related party transaction

Details of other related party

transaction

Value of the related party	Remarks on approval
transaction as approved	by audit committee
by the audit committee

entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.

	In case monies are	In case any financial indebtedness is incurred to
	due to either party as	make or give loans, inter-corporate deposits,		Details of the loans, inter-corporate deposits, advances or investments
	a result of the	advances or investments
Value of transaction			Nature of			Nature (loan/
during the reporting								Purpose for which the funds Notes
		indebtedness	Details of		advance/
period	Opening	Closing					will be utilised by the
(loan/ issuance of	other	Cost Tenure	intercorporate	Interest Rate (%)	Tenure	Secured/ unsecured
	balance	balance	ultimate recipient of funds
	debt/ any other	indebtedness		deposit/
							(end usage)
			etc.)			investment )

370	Cipla Medpro South Africa Pty	Brandmed (Pty) Limited
	Ltd
371	Medpro Pharmaceutica Pty Ltd	Cipla Foundation (South Africa)

Associate

Interest received

Entities over which the company Any other transaction is able to exercise significant

influence/Control

Trade and Other receivable

0.84 Approved

Not applicable

0.84	-	-
-	0.03	0.19

372	Cipla Medpro South Africa Pty	Cipla Medpro Manufacturing Pty Ltd	Subsidiary	Dividend Received		-	Not applicable	44.21	-	-
	Ltd
373	Cipla Kenya Limited	Cipla Quality Chemical Industries Limited	Subsidiary	Any other transaction	Trade and Other receivable	-	Not applicable	-	-	-
374	Medpro Pharmaceutica Pty Ltd	Cipla-Medpro Distribution Centre (Pty) Limited	Subsidiary	Any other transaction	Trade and Other payable	-	Not applicable	-	0.17	1.21
375	Medpro Pharmaceutica Pty Ltd	Cipla-Medpro Pty Ltd	Subsidiary	Any other transaction	Trade and Other receivable	-	Not applicable	-	-354.59	5.67
376	Medpro Pharmaceutica Pty Ltd	Cipla-Medpro Pty Ltd	Subsidiary	Any other transaction	Reimbursement charges	50.00	Approved	1.72	-	-
					received
377	Cipla Medpro South Africa Pty	Cipla Medpro Pty Ltd	Subsidiary	Dividend Received		-	Not applicable	353.64	-	-
	Ltd
378	Medpro Pharmaceutica Pty Ltd	Cipla Quality Chemical Industries Limited	Subsidiary	Purchase of goods or services		50.00	Approved	5.78	-	-
379	Medpro Pharmaceutica Pty Ltd	Cipla Quality Chemical Industries Limited	Subsidiary	Any other transaction	Trade and Other payable	-	Not applicable	-	11.09	-
380	Medpro Pharmaceutica Pty Ltd	Cipla Quality Chemical Industries Limited	Subsidiary	Any other transaction	Trade and Other receivable	-		-	0.05	-
381	Medpro Pharmaceutica Pty Ltd	Cipla Select Pty Ltd	Subsidiary	Any other transaction	Trade and Other receivable	-	Not applicable	-	14.71	2.80
382	Medpro Pharmaceutica Pty Ltd	Cipla Select Pty Ltd	Subsidiary	Any other transaction	Reimbursement charges	6.00	Approved	1.51	-	-
					received
383	Cipla Medpro Botswana	Medpro Pharmaceutica Pty Ltd	Subsidiary	Any other transaction	Trade and Other receivable	-	Not applicable	-	0.00	0.00
	Proprietary Limited
384	Medpro Pharmaceutica Pty Ltd	Cipla Medpro South Africa (Pty) Limited	Subsidiary	Any other transaction	Loan payable	742.65	Approved	742.65	-	-758.41	Loan	250 bps higher than 3 months JIBAR	Repayament starts with 31	Unsecured	Working Capital and capital
												rate capped at the prime lending rate	March 2026 to Oct 2029		expenditure
												in South Africa
385	Medpro Pharmaceutica Pty Ltd	Cipla Medpro South Africa (Pty) Limited	Subsidiary	Any other transaction	Interest paid	24.53	Approved	24.53	-	-
386	Cipla Medpro South Africa Pty	Medpro Pharmaceutica Pty Ltd	Subsidiary	Any other transaction	Trade and Other payable	-	Not applicable	-	152.15	302.30
	Ltd
387	Cipla Medpro South Africa Pty	Medpro Pharmaceutica Pty Ltd	Subsidiary	Any other transaction	Reimbursement charges	165.00	Approved	71.89	-	-
	Ltd				received
388	Mirren Pty Ltd	Medpro Pharmaceutica Pty Ltd	Subsidiary	Any other transaction	Trade and Other receivable	-	Not applicable	-	3.95	4.63
389	Cipla Medpro South Africa Pty	Cipla Medpro Manufacturing Pty Ltd	Subsidiary	Any other transaction	Reimbursement charges	20.00	Approved	2.77	-	-
	Ltd				received
390	Cipla Medpro South Africa Pty	Cipla Medpro Pty Ltd	Subsidiary	Any other transaction	Trade and Other receivable	-	Not applicable	-	1.90	1.88
	Ltd
391	Medpro Pharmaceutica Pty Ltd	Cipla Medpro Manufacturing Pty Ltd	Subsidiary	Any other transaction	Reimbursement charges	-	Not applicable	15.83	-	-
					received
392	Medpro Pharmaceutica Pty Ltd	Cipla Medpro Manufacturing Pty Ltd	Subsidiary	Sale of goods or services		-	Not applicable	38.94	-	-
393	Medpro Pharmaceutica Pty Ltd	Cipla Medpro Manufacturing Pty Ltd	Subsidiary	Any other transaction	Trade and Other receivable	-	Not applicable	-	3.94	143.45
394	Medpro Pharmaceutica Pty Ltd	Mirren Pty Ltd	Subsidiary	Any other transaction	Trade and Other receivable	-	Not applicable	-	47.70	48.00
395	Medpro Pharmaceutica Pty Ltd	Mirren Pty Ltd	Subsidiary	Any other transaction	Reimbursement charges	8.00	Approved	0.84	-	-
					received
396	Medpro Pharmaceutica Pty Ltd	Cipla Kenya Limited	Subsidiary	Any other transaction	Trade and Other receivable	-	Not applicable	-	22.75	23.54
397	Medpro Pharmaceutica Pty Ltd	Cipla Kenya Limited	Subsidiary	Any other transaction	Reimbursement charges	5.00	Approved	1.06	-	-
					received
398	Cipla Medpro Distribution	Cipla Kenya Limited	Subsidiary	Any other transaction	Trade and Other receivable	-	Not applicable	-	0.24	0.23
	Centre Pty Ltd
399	Cipla Medpro Manufacturing	Cipla Medpro South Africa (Pty) Limited	Subsidiary	Any other transaction	Trade and Other receivable	-	Not applicable	-	17.54	0.52
	Pty Ltd
400	Cipla Medpro South Africa Pty	Cipla Medpro Manufacturing Pty Ltd	Subsidiary	Any other transaction	Trade and Other receivable	-	Not applicable	-	9.64	28.84
	Ltd
401	Cipla Medpro South Africa Pty	Cipla Medpro Manufacturing Pty Ltd	Subsidiary	Any other transaction	Royalty Income	35.00	Approved	16.98	-	-
	Ltd
402	Cipla Empowerment Trust	Cipla Foundation (South Africa)	Entities over which the company Any other transaction	Distribution	4.00	Approved	0.22	-	-
			is able to exercise significant
			influence/Control
403	Cipla Medpro Manufacturing	Cipla Empowerment Trust	Entities over which the company Advance		-		-	0.00	0.00
	Pty Ltd		is able to exercise significant
			influence/Control
404	Cipla Select Pty Ltd	Medpro Pharmaceutica Pty Ltd	Subsidiary	Any other transaction	Trade and Other receivable	-	Not applicable	-	0.89	0.86
405	Cipla Select Pty Ltd	Medpro Pharmaceutica Pty Ltd	Subsidiary	Sale of goods or services		-	Not applicable	0.78	-	-
406	Actor Proprietary Limited	Medpro Pharmaceutica Pty Ltd	Subsidiary	Any other transaction	Trade and Other receivable	-	Not applicable	-	-	30.07
407	Actor Proprietary Limited	Medpro Pharmaceutica Pty Ltd	Subsidiary	Sale of goods or services		26.15	Approved	26.15	-	-
408	Medpro Pharmaceutica Pty Ltd	Cipla Australia Pty Ltd	Subsidiary	Any other transaction	Trade and Other receivable	-	Not applicable	-	-	0.37
409	Medpro Pharmaceutica Pty Ltd	Cipla Australia Pty Ltd	Subsidiary	Any other transaction	Reimbursement charges	-	Not applicable	0.38	-	-
					received
410	Medpro Pharmaceutica Pty Ltd	Genevieve Mannel	Key Management Personnel of	Remuneration		-		0.56	-	-
			Subsidiary
411	Medpro Pharmaceutica Pty Ltd	Sheron Yolande Chirwa	Key Management Personnel of	Remuneration		-		0.72	-	-
			Subsidiary
412	Medpro Pharmaceutica Pty Ltd	Mark Warwick Daly	Key Management Personnel of	Remuneration		-		1.11	-	-
			Subsidiary
413	Medpro Pharmaceutica Pty Ltd	Oscar Manuga	Key Management Personnel of	Remuneration		-		0.74	-	-
			Subsidiary
414	Medpro Pharmaceutica Pty Ltd	Simo Masondo	Key Management Personnel of	Remuneration		-		0.74	-	-
			Subsidiary
415	Medpro Pharmaceutica Pty Ltd	James Paul Miller	Key Management Personnel of	Remuneration		-		1.48	-	-
			Subsidiary
416	Medpro Pharmaceutica Pty Ltd	Prabavathie Thandrind	Key Management Personnel of	Remuneration		-		0.68	-	-
			Subsidiary
417	Cipla Kenya Limited	Joan Wakori	Key Management Personnel of	Remuneration		-		0.18	-	-
			Subsidiary
418	Cipla Kenya Limited	Kaustubh Deshpande	Key Management Personnel of	Remuneration		-		0.89	-	-
			Subsidiary
419	Cipla Kenya Limited	Catherine Kagai	Key Management Personnel of	Remuneration		-		0.42	-	-
			Subsidiary
420	Cipla Kenya Limited	Megha Bhatt	Key Management Personnel of	Remuneration		-		0.14	-	-
			Subsidiary

entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.

	Details of the party (listed entity /subsidiary)									In case monies are	In case any financial indebtedness is incurred to
	Details of the counterparty							due to either party as	make or give loans, inter-corporate deposits,
	entering into the transaction
Sr No.									a result of the	advances or investments

							Value of the related party		Value of transaction
							Details of other related party	Remarks on approval			Nature of			Nature (loan/
					Relationship of the counterparty	Type of related party transaction	transaction as approved	during the reporting			Details of
						transaction	by the audit committee	by audit committee	period	Opening	Closing	indebtedness		advance/
	Name	PAN	Name	PAN	with the listed entity or its				(loan/ issuance of	other	Cost Tenure	intercorporate
						balance	balance
					subsidiary						debt/ any other	indebtedness		deposit/

													etc.)		investment )
421	Actor Proprietary Limited		Medpro Pharmaceutica Pty Ltd		Subsidiary	Any other transaction	Royalty income	0.38	Approved	0.38	-	-
422	Aspergen Inc.		Cipla USA Inc.		Subsidiaries	Purchase of goods or services		20.00	Approved	2.32	-	-
423	Aspergen Inc.		Cipla USA Inc.		Subsidiaries	Any other transaction	Trade and Other Payables	100.00	Approved	-	-	-
424	Aspergen Inc.		Kemwell Biopharma Private Limited		Related party of subsidiary	Purchase of goods or services		19.95	Approved	30.77	-	-
425	Aspergen Inc.		Kemwell Biopharma UK Limited		Related party of subsidiary	Any other transaction	Issue of share capital	-		19.95	-	-
426	Aspergen Inc.		Kemwell Biopharma Private Limited		Related party of subsidiary	Any other transaction	Trade and Other Payables	110.00	Approved	-	-	-
427	Cipla USA Inc.		Invagen Pharmaceuticals Inc.		Subsidiaries	Any other transaction	Reimbursement Charges	20.00	Approved	5.34	-	-
							Received
428	Cipla USA Inc.		Exelan Pharmaceuticals Inc.		Subsidiaries	Any other transaction	Reimbursement Charges	3.00	Approved	3.39	-	-
							Received
429	Cipla USA Inc.		Cipla Technologies LLC.		Subsidiaries	Any other transaction	Reimbursement Charges	-		0.42	-	-
							Received
430	Cipla USA Inc.		Umang Vohra		Key Management Personnel of	Remuneration		-		3.12	-	-
					Subsidiary
431	Cipla USA Inc.		Arunesh Verma		Key Management Personnel of	Remuneration		-		1.76	-	-
					Subsidiary
432	Cipla USA Inc.		Arunesh Verma		Key Management Personnel of	Remuneration		-		4.26	-	-
					Subsidiary
433	Cipla USA Inc.		Srinivas Mallavarapu		Key Management Personnel of	Remuneration		-		1.60	-	-
					Subsidiary
434	Cipla USA Inc.		Sudipta Ganguly		Key Management Personnel of	Remuneration		-		1.10	-	-
					Subsidiary
435	Cipla USA Inc.		Deepak Agrawal		Key Management Personnel of	Remuneration		-		1.37	-	-
					Subsidiary
436	Cipla USA Inc.		Biplab Mazumdar		Key Management Personnel of	Remuneration		1,100.00	Approved	1.03	-	-
					Subsidiary
437	Invagen Pharmaceuticals Inc.		Cipla USA Inc.		Subsidiaries	Sale of goods or services		-	Not applicable	184.59	-	-
438	Invagen Pharmaceuticals Inc.		Cipla USA Inc.		Subsidiaries	Sale of goods or services		215.00	Approved	126.66	-	-
439	Invagen Pharmaceuticals Inc.		Cipla USA Inc.		Subsidiaries	Any other transaction	Reimbursement Charges	1,100.00	Approved	120.19	-	-
							Received
440	Invagen Pharmaceuticals Inc.		Exelan Pharmaceuticals Inc.		Subsidiaries	Sale of goods or services		24.94	Approved	366.76	-	-
441	Invagen Pharmaceuticals Inc.		Cipla Therapeutics Inc.		Subsidiaries	Investment		-		24.94	-	-
442	Invagen Pharmaceuticals Inc.		Robert Stewart		Key Management Personnel of	Any other transaction	Sitting Fees/Commission and	-		0.17	-	-
					Subsidiary		Other Benefits
443	Invagen Pharmaceuticals Inc.		Anup Dad		Key Management Personnel of	Remuneration		-	Not applicable	0.78	-	-
					Subsidiary
444	Exelan Pharmaceuticals Inc.		Invagen Pharmaceuticals Inc.		Subsidiaries	Any other transaction	Reimbursement Charges	-	Not applicable	20.34	-	-
							Received
445	Exelan Pharmaceuticals Inc.		Invagen Pharmaceuticals Inc.		Subsidiaries	Any other transaction	Reimbursement Charges	-		5.22	-	-
							Received
446	Exelan Pharmaceuticals Inc.		Brian Christensen		Key Management Personnel of	Remuneration		-		1.48	-	-
					Subsidiary
447	Exelan Pharmaceuticals Inc.		Atul Sant		Key Management Personnel of	Remuneration		53.45	Approved	1.53	-	-
					Subsidiary
448	Cipla Technologies LLC		Invagen Pharmaceuticals Inc.		Subsidiaries	Any other transaction	Reimbursement Charges	1.00	Approved	48.58	-	-
							Received
449	Cipla Therapeutics Inc.		Cipla Technologies LLC.		Subsidiaries	Any other transaction	Reimbursement Charges	-		0.02	-	-
							Received
450	Cipla Therapeutics Inc.		Elizabeth Garrett Ingram		Key Management Personnel of	Remuneration		-		2.22	-	-
					Subsidiary
451	Cipla Therapeutics Inc.		Robert Nyen		Key Management Personnel of	Remuneration		-		1.28	-	-
					Subsidiary
452	Cipla Therapeutics Inc.		Ashok Nayak		Key Management Personnel of	Remuneration		33.26	Approved	0.66	-	-
					Subsidiary
453	Invagen Pharmaceuticals Inc.		Cipla Technologies LLC.		Subsidiaries	Investment		-		33.26	-	-
454	Cipla USA Inc.		Exelan Pharmaceuticals Inc.		Subsidiaries	Any other transaction	Trade and other receivables	-		-	0.03	-
455	Cipla USA Inc.		Cipla Technologies LLC.		Subsidiaries	Any other transaction	Trade and other receivables	-		-	0.07	-
456	Aspergen Inc.		Kemwell Biopharma Private Limited		Related party of subsidiary	Any other transaction	Trade and Other Payables	-		-	20.00	24.81
457	Cipla USA Inc.		Invagen Pharmaceuticals Inc.		Subsidiaries	Any other transaction	Trade and other receivables	-		-	235.03	289.98
458	Cipla USA Inc.		Aspergen Inc.		Subsidiaries	Any other transaction	Trade and other receivables	-		-	2.57	2.12
459	Invagen Pharmaceuticals Inc.		Exelan Pharmaceuticals Inc.		Subsidiaries	Any other transaction	Trade and other receivables	-		-	126.90	273.41
460	Cipla Technologies LLC		Invagen Pharmaceuticals Inc.		Subsidiaries	Any other transaction	Trade and other receivables	1.00	Approved	-	35.51	84.39
461	Exelan Pharmaceuticals Inc.		Cipla USA Inc.		Subsidiaries	Any other transaction	Reimbursement Charges	-		0.06	-	-
							Received
462	Cipla USA Inc.		Pradeep Bhaduria		Key Management Personnel of	Remuneration		12.00		4.43	-	-
					Subsidiary
463	Cipla (China) Pharmaceutical		Cipla (Jiangsu) Pharmaceutical Co. Limited		Subsidiaries	Any other transaction	Reimbursement charges	-		0.77	-	-
	Co., Ltd						received
464	Cipla (China) Pharmaceutical		Wang Chunyi		Key Management Personnel of	Remuneration		-		0.22	-	-
	Co., Ltd				Subsidiary
465	Cipla (China) Pharmaceutical		Sridhar Subramanian		Key Management Personnel of	Remuneration		-		1.51	-	-
	Co., Ltd				Subsidiary
466	Cipla (China) Pharmaceutical		Cipla (Jiangsu) Pharmaceutical Co. Limited		Subsidiaries	Any other transaction	Trade and Other Receivables	-		-	1.03	0.36
	Co., Ltd
467	Cipla Europe NV		Cipla Australia Pty Ltd		Subsidiaries	Any other transaction	Trade and Other Receivables	-		-	0.11	-
468	Cipla Australia Pty Ltd		Jigneshkumar Harsadrai Desai		Key Management Personnel of	Remuneration		-		0.36	-	-
					Subsidiary
469	Cipla Australia Pty Ltd		Stephen Fraser		Key Management Personnel of	Remuneration		-		0.11	-	-
					Subsidiary
470	Cipla Australia Pty Ltd		Cipla Gulf FZ - LLC		Subsidiaries	Any other transaction	Trade and Other Receivables	-		-	-	1.51
471	Cipla Brasil Importadora E		Gaurav Datay		Key Management Personnel of	Any other transaction	Sitting Fees/Commission and	-		0.02	-	-
	Distribuidora De				Subsidiary		Other Benefits
	Medicamentos Ltda
472	Cipla Colombia SAS		Gaurav Datay		Key Management Personnel of	Remuneration		2.00	Approved	0.49	-	-
					Subsidiary
473	Cipla Colombia SAS		Gaurav Datay		Key Management Personnel of	Any other transaction	Sitting Fees/Commission and	20.00	Approved	0.30	-	-
					Subsidiary		Other Benefits
474	Cipla Europe NV		Cipla (EU) Limited		Subsidiaries	Purchase of goods or services		-	Not applicable	6.16	-	-
475	Cipla Europe NV		Cipla (EU) Limited		Subsidiaries	Any other transaction	Trade and Other Receivables	60.00	Approved	-	1.48	2.10

Details of the loans, inter-corporate deposits, advances or investments
			Purpose for which the funds Notes
Interest Rate (%)	Tenure	Secured/ unsecured	will be utilised by the
ultimate recipient of funds

(end usage)

Attachments

Original Link
Original Document
Permalink

Disclaimer

Cipla Ltd. published this content on 11 May 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 11 May 2024 04:13:08 UTC.

Delayed NSE India S.E. Other stock markets 00:45:35 2024-05-23 EDT			5-day change	1st Jan Change
1,484 ^INR	+0.13%		+4.45%	+19.10%

05-22	Consumer Goods, Realty Push Indian Equities Higher on Wednesday	MT
05-22	Cipla Arm Gets US FDA Final Nod for Lanreotide Injection	MT

Consumer Goods, Realty Push Indian Equities Higher on Wednesday	05-22	MT
Cipla Arm Gets US FDA Final Nod for Lanreotide Injection	05-22	MT
Cipla Limited Approves the Appointment of Dr. Balram Bhargava as an Independent Director	05-17	CI
Indian Equities Extend Gains on Friday, Led by Real Estate, Auto and Metal Names	05-17	MT
Cipla Invests INR260 Million More in Associate Achira Labs	05-15	MT
Indian Equities Posts Mild Losses on Wednesday Ahead of US Consumer Inflation Data	05-15	MT
INDIA STOCKS-Cipla lifts Indian shares at the open; Canara Bank rises on MSCI inclusion	05-15	RE
Achira Labs Pvt. Ltd. announced that it expects to receive INR 260 million in funding from Cipla Limited	05-14	CI
Cipla Limited Announces Resignation of Jasdeep Singh as Chief Strategy Officer and Senior Management Personnel	05-14	CI
Promoter group to sell stake worth $316 million in India's Cipla, CNBC-TV18 reports	05-14	RE
Indian Equities Close Higher on Tuesday, Led by Auto, Metal Stocks	05-14	MT
Nomura Adjusts Cipla’s Price Target to INR1,486 From INR1,569, Keeps at Neutral	05-14	MT
Indian Equities End Higher on Monday Despite Poll Worries, Foreign Selling	05-13	MT
Jefferies Adjusts Cipla’s Price Target to INR1,400 From INR1,250, Keeps at Hold	05-13	MT
Cipla's Consolidated Net Profit Climbs in Fiscal Q4; Shares Up 6%	05-13	MT
INDIA STOCKS-Election worries, foreign selling spook Indian equities; volatility climbs	05-13	RE
INDIA STOCKS-Indian shares fall as Tata Motors slides; inflation data awaited	05-13	RE
Transcript : Cipla Limited, Q4 2024 Earnings Call, May 10, 2024	05-10
Market Heavyweights Lifts Indian Equities to End Week Higher	05-10	MT
India's Cipla open to partnering with Eli Lilly to market their obesity drugs, CEO says	05-10	RE
India's Cipla beats Q4 profit estimates	05-10	RE
Cipla Limited Recommends Payment of Final Dividend for the Financial Year Ended March 31, 2024	05-10	CI
Cipla Limited Announces Retirement of S. Radhakrishnan as Non-Executive Director	05-10	CI
Cipla Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024	05-10	CI
India's Alembic Pharma posts higher Q4 profit on strong N.America sales	05-09	RE

	1st Jan change	Capi.
CIPLA LIMITED	+18.47%	13.98B
OTSUKA HOLDINGS CO., LTD.	+18.62%	22.46B
SANDOZ GROUP AG	+18.55%	15.04B
ZYDUS LIFESCIENCES LIMITED	+59.28%	13.15B
ONO PHARMACEUTICAL CO., LTD.	-9.68%	6.89B
THE MEDICINES COMPANY	-0.05%	6.79B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+13.66%	5.71B
RICHTER GEDEON VEGYÉSZETI GYÁR NYILVÁNOSAN MUKÖDO RT.	+4.00%	4.69B
SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD.	-13.26%	4.33B

Cipla Limited

Equities

CIPLA

INE059A01026

Pharmaceuticals

Cipla : Disclosure of Related Party Transactions for the half year ended 31st March 2024

Latest news about Cipla Limited

Chart Cipla Limited

Company Profile

Income Statement Evolution

Ratings for Cipla Limited

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Generic Pharmaceuticals